Real Stock Plays

[ProfitScout]

$ONAR News: Onar Holding Corporation Announces FINRA Approval for New Name and Ticker Symbol, ONAR

This final step in ONAR's reverse merger journey sets the stage for ambitious growth, strategic acquisitions, and market expansion.

LOS ANGELES, Feb. 3, 2025 /PRNewswire/ -- Reliant Holdings, Inc. (OTCQB: ONAR), a leading marketing technology company and network of marketing agencies, today announced that it has received approval from the Financial Industry Regulatory Authority (FINRA) to formally adopt its new corporate name and change its ticker symbol from RELT to ONAR. Effective immediately, these updates underscore the company's reverse merger completion, forward-looking vision, and commitment to accelerated growth in an increasingly competitive marketplace.

"This transformation marks a significant milestone for our organization," said Claude Zdanow, CEO of ONAR. "By unifying our identity under a single, modernized brand, we're better positioned to pursue our ambitious goals, drive innovation, and deliver exceptional results for our clients, partners, and investors."

A Unified Brand with a Bold Vision

The new corporate name and ticker symbol reflect ONAR's evolution following its reverse merger with Reliant Holdings, Inc. in 2024. This streamlined identity removes confusion and clarifies that ONAR's market presence aligns with its strategic mission: to offer state-of-the-art marketing solutions, blending AI-driven technology with human expertise to help businesses thrive in today's digital landscape.

Key Advantages of the Name Change & Finalization of the Rebrand

Increased Market Visibility: The updated name and ticker symbol help investors and stakeholders easily recognize ONAR and its position as a marketing technology leader and remove the confusion with the Reliant Holdings brand that had no connection to ONAR's business.

Improved Brand Perception: By aligning the company's identity with its current strategy and market positioning, ONAR is confident this will enhance market visibility, improve brand perception, and signal its commitment to growth and innovation.
Milestones Driving Momentum

This updated company identity comes less than one year after ONAR's reverse merger with Reliant Holdings Inc. In the months since the merger, ONAR has achieved significant milestones, including:

Launching ONAR Labs: Introduced Cortex, an AI-powered marketing intelligence platform revolutionizing data-driven decision-making.

CEO Leadership: Claude Zdanow presented their ambitious vision at the 2025 Sequire Investor Summit and NobleCon20.

Strategic Partnerships: Secured a mid-six-figure contract with iQSTEL, Inc. to lead their rebranding and growth initiatives.

Executive Team Expansion: Appointed Patricia Kaelin as Chief Financial Officer and welcomed Sara Scully as corporate communications and marketing leader.

Financial Growth: Achieved robust Q3 2024 results, featuring higher revenue, lower costs, and a stronger cash position.

Acquisitions and Expanded Reach: Acquired and rebranded Of Kos, adding healthcare marketing expertise and expanding their global network.

Shareholder Confidence: Gained formal approval for the name change to Onar Holding Corporation and authorized amendments to fuel future expansion.

Rebranding for Success: Revitalized flagship agency Storia with fresh visuals, emphasizing performance marketing and AI-driven optimization.
These achievements reflect ONAR's commitment to innovation, strategic growth, and leveling the playing field for middle-market and growth-stage companies so they may achieve marketing success in an increasingly competitive landscape.

The team is incredibly proud of the progress made in such a short time and excited for the future as they continue to revolutionize the advertising and marketing industry. ONAR leaders are confident that the company is well-positioned for continued success and look forward to delivering exceptional results for clients, partners, and shareholders in 2025.

About ONAR

ONAR (OTCQB: ONAR) a leading marketing technology company and marketing agency network, now publicly traded as Onar Holding Corporation. ONAR's mission is to provide unparalleled service through an integrated, AI-driven approach, leveraging its diverse brand family's strengths. Committed to honor, candor, and best-in-class results, ONAR aims to lead the industry by example, ensuring every client relationship is deeply rooted in trust and excellence.

ONAR has nearly 50 employees across five continents, and it is aggressively expanding its team to support the company's growth and acquisition pipeline. Its agencies service over 45 clients across various industries:

Performance Marketing & SEO: Our high-touch performance marketing agency, Storia, specializes in brand growth, data-driven excellence, and paid advertising.
Full-Service Healthcare Marketing: Partnering with healthcare professionals, Of Kos provides the best possible patient experience and strives to revolutionize the standard of care.
Experiential Marketing & Events: CHALK is an experiential marketing powerhouse of event architects who turn bold ideas into unforgettable reality, designing events that dare to defy the ordinary.
Pioneering Technology Incubator: ONAR Labs is a team of data scientists, engineers, and industry experts who are identifying, developing, and commercializing innovative marketing technology solutions born from servicing our agency clients, battle-tested by our network to ensure real-world applicability and impact.
ONAR's network of agencies focuses on servicing companies ranging from $50M to $1B+ in revenue, and ONAR is actively searching for agencies to acquire and become part of the network.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ONAR's current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are not historical facts and are inherently uncertain and outside of ONAR's control. Forward-looking statements include, among other things, statements regarding ONAR's expectations regarding its ability to achieve its financial and strategic goals, including surpassing $100 million in revenue and securing a NASDAQ listing; its ability to expand its client base and market share; and its ability to develop and launch new products and services. Actual results may differ materially from ONAR's expectations and projections due to various risks and uncertainties, including market conditions, competition, the ability to protect intellectual property, the ability to manage growth, changes in laws and regulations, and other factors described in ONAR's filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and ONAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/onar-holding-corporation-announces-finra-approval-for-new-name-and-ticker-symbol-onar-302365949.html

SOURCE ONAR

[ProfitScout]

$IVDN Feature: Record Sales Growth for Patented, "Evacuated Cell" Insulation Delivering Superior R-6 Rating & Other Advanced Specs to Meet New Government Building Codes: Innovative Designs, Inc. (Stock Symbol: IVDN)
01-13-2025 12:16 PM CET
Link:
http://markets.financialcontent.com/streetinsider/article/getnews-2025-1-13-record-sales-growth-for-patented-evacuated-cell-insulation-delivering-superior-r-6-rating-and-other-advanced-specs-to-meet-new-government-building-codes-innovative-designs-inc-stock-symbol-ivdn/

[Golden Cross]

$TORVF Predicting the Future of EV Batteries - Volt Carbon Technologies
https://youtube.com/watch?v=bssQwaXIDVc

[ProfitScout]

$XONI News: Xtreme Fighting Championships Relaunches Young Guns Series at Kill Cliff Fight Club Live on January 29th, 2025

DETROIT, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Xtreme Fighting Championships (XFC) presented by Xtreme One Entertainment, Inc. (OTC: XONI) today announced the return of their Young Guns series, showcasing MMA’s most ambitious new prospective talent. Originally launched in 2020, XFC Young Guns will return Wednesday, January 29th at the renowned Kill Cliff Fight Club in Deerfield Beach, Florida, commencing a multi-event deal.

The XFC’s Young Guns series serves as a proving ground for emerging male and female mixed martial arts athletes that aspire to rise through the ranks and fight in the “big leagues” of MMA, the UFC. Kicking off in January 2025, XFC will present six Young Guns events in the U.S. throughout the year and is in discussions to bring Young Guns to Latin America.

“Knowing the proven history of our Young Guns series and the amount of MMA superstars waiting to be discovered, we identified early on that relaunching Young Guns was our top priority,” said Chris Defendis, President of Xtreme One Entertainment. “We secured Kill Cliff Fight Club in South Florida to serve as our venue partner, and we already have a great group of athletes ready to fight for their future as the next great rising star in MMA. Following the successful execution of our three arena events in 2024, XFC is ringing in 2025 with a brand-new Young Guns live and a series of events that will be must-watch TV.”

"We have been impressed with XFC as a promotion for many years now,” said Jamie Gall, General Manager, Kill Cliff FC. “After having the opportunity to work with them in 2024, experiencing their professionalism, passion, and ingenuity, we’re eager to host Young Guns at our facility. At Kill Cliff FC, we offer the professional environment our athletes deserve and create opportunities for our athletes outside the norm of this sport. XFC's vision for Young Guns aligns with ours, as well as the needs of our athletes and MMA athletes globally in search of a promotion to propel them to the next level.”

The relaunch of Young Guns is a key component of the XFC’s strategy to discover the next generation of MMA talent, serving as the development league for future world contenders and champions.

“We have the team and platform to spotlight the best up-and-coming talent, and we’re committed as an organization to also be a partner and catalyst in the careers of MMA fighters building their profiles and chasing their dreams,” Defendis added.

After a successful run of momentum-building events in 2024, such as XFC Grand Prix II and XFC 51:Evolution, the XFC plans to raise the bar in 2025 by providing more action-packed content and expanding the XFC community. To learn more about XFC Young Guns, buy exclusive XFC licensed merchandise or for information on other upcoming XFC events, fans can visit XFCFight.com.

About Xtreme One Entertainment, Inc.
Founded in 1995 as a consumer and diversified holding company Xtreme One Entertainment, Inc. (OTC: XONI) is now focused on media, entertainment, live sports, and event marketing focused on extreme sports events. XtremeOne, through its wholly owned subsidiary, XFC Global, Inc. is the holder of an exclusive and perpetual license to the brands and intellectual property of Xtreme Fighting Championships (XFC).

For more information, please contact:

Media:
Jen Wenk
[e-mail]

Investors:
Zachary Mizener
[e-mail]

[ProfitScout]

$BLIS News on Pending $370 Million Contract: NAPC Defense (OTCPK: BLIS) issues new Progress Report regarding Large Contract with Saudi Arabia, Live-Fire Demos for U.S. based Police and SWAT, Manufacturing update, and more

LARGO, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that the Company is making strong progress on its CornerShot USA weapons systems and other initiatives.

NAPC’s Management believes the Company is well positioned to drive significant revenue and profits in 2025, from its own manufacturing and sale of CornerShot in the United States and Saudi Arabia. NAPC maintains it will also drive revenue through the brokering of arms and munitions, as well as contract work for renovation and clean up, following recent hurricanes in the area.

As previously announced, NAPC received a signed and stamped Letter of Intent from Saudi Arabia for an initial order of 37,000 CornerShot units, valued at (U.S.) $370 million. Management has already conducted critical late-stage meetings and live-fire demonstrations in Saudi Arabia with several military divisions through visits to the country in August and October of 2024.

NAPC Defense has now received a request to complete live fire demonstrations in Saudi Arabia from Saudi Land Forces. The visit is planned to take place between December 29, 2024 and January 12, 2025. The Company previously reported that this upcoming visit would take place last month.

Please see below for a list of current and anticipated NAPC developments, as we enter the New Year:

Following the next phase of the upcoming CornerShot demonstrations in Saudi Arabia, NAPC expects that it will enter final contract negotiations, deposit funding, and initial CornerShot manufacturing. in Q1 of 2025.
NAPC has secured manufacturing facilities for the production of CornerShot USA weapons systems in Pinellas Park, FL. The space is large enough to meet anticipated demand for the near future.
Live-fire demonstrations were recently conducted for St. Petersburg Police and SWAT teams in Pinellas County. New orders from these departments, as well as others, are expected in January 2025.
NAPC Defense has secured booth space #10953 at the upcoming SHOT Show in Las Vegas from January 21-24, 2025. The SHOT Show is the largest and most comprehensive trade show for all professionals involved with the shooting sports, hunting and law enforcement industries.
In addition to over $1.5 million in new hurricane renovation and cleanup work in Pinellas Country, the Company has partnered with another firm in an effort to win an additional $3 million in contracts.
CEO Kenny West stated, “This is truly an exciting time for NAPC Defense. We have laid the groundwork in 2024, and now it’s time to deliver in 2025. We appreciate the ongoing support from our shareholders and investors.”

About NAPC Defense, Inc.

NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.

FORWARD LOOKING STATEMENTS:

This press release and the statements of representatives of NAPC (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information.

These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should,’ “believes," "expects," "anticipates,” “estimates," "intends," "plans, “ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.

COMPANY CONTACT:

Kenny West, CEO [phone] Ext.713

https://www.globenewswire.com/newsroom/ti?nf=OTMxODA3MiM2NjM0MDk5IzIyNjE1MDY=
https://ml.globenewswire.com/media/ZTE0MTNkZDEtNzcyMi00YmU0LTk2YTEtMThmMDA4NDI4NGEwLTEyNzMwNTY=/tiny/NAPC-Defense-Inc-.png

Source: NAPC Defense, Inc.

[Golden Cross]

$ILLR David Feldman talks BKFC's Growth
https://youtube.com/watch?v=Sx-yii9CMmE

[ProfitScout]

$IQST - iQSTEL Releases Q3 FY-2024 Shareholder Letter Highlighting Record Growth, Strategic Expansion, and Nasdaq Uplisting Progress

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- iQSTEL Inc. (OTCQX: IQST), a leading innovator in telecommunications and technology, proudly announces the release of its Q3 FY-2024 Shareholder Letter, coinciding with the SEC filing of its 10-Q for the Q3. This letter showcases an extraordinary quarter marked by strategic growth, robust financial performance, and significant advancements toward iQSTEL's long-term vision, including preparations for a Nasdaq uplisting.

The Shareholder Letter covers key highlights for the nine-month period ended September 30, 2024, showcasing iQSTEL's rapid revenue growth, profitability in its core Telecom Division, and ongoing advancements in high-margin, cutting-edge products including AI and cybersecurity solutions.

"We're exceptionally proud of our achievements this quarter, and we believe our performance confirms the strength of iQSTEL's strategy and position in the market," said Leandro Jose Iglesias, CEO of iQSTEL. "With record-breaking growth, innovative new offerings, and solid progress toward our Nasdaq uplisting, iQSTEL is positioned for unprecedented success as we look ahead to 2025 and beyond."

In alignment with its commitment to becoming a $1 billion revenue company by 2027, iQSTEL has developed a comprehensive business plan supported by its newly established corporate financial planning department. This department will work closely with our subsidiaries on a monthly basis to drive bottom-line improvements, setting the stage for significant profitability gains beginning in FY-2025.

Additionally, iQSTEL's Independent Board of Directors and dedicated investor base continue to demonstrate strong support for the company's vision and growth strategy, underscoring our shared commitment to building a premier, high-growth technology powerhouse.

The Q3 Shareholder Letter highlights the following key developments:

Record Revenue Growth: Revenue for the first nine months reached $184 million, an impressive 89% year-over-year increase.
Ambitious FY-2024 Revenue Target: iQSTEL aims for a record $290 million in revenue for FY-2024, with strong expectations for Q4, driven by its subsidiary QXTEL.
Profitability in Telecom Division: The Telecom Division achieved solid profitability, generating $548,274 in profit for Q3 alone.
Strategic Cost Savings: A consolidation strategy within the Telecom Division is expected to save up to $2 million annually.
Nasdaq Uplisting Progress: iQSTEL's stockholders' equity has met Nasdaq's minimum requirements, with final investment bank selection underway to guide the uplisting process.
Global Reach: iQSTEL now operates with 100 employees across 20 countries, with six offices providing 24/7 support across 17 time zones.
Launch of High-Tech, High-Margin Products: The company has introduced AI-driven AIRWEB.ai and preparing to launch a cybersecurity solution in Q1 FY-2025.
The Shareholder Letter concludes with an optimistic outlook for iQSTEL's trajectory as the company continues to pursue its $1 billion revenue goal by 2027.

The full Shareholder Letter can be found below:

Dear Shareholders,

We are thrilled to present our Q3 FY-2024 results, which highlight an extraordinary period of growth and strategic advancement for iQSTEL. This quarter has firmly positioned us on a path to unprecedented success, and we're eager to share the positive progress we're making.

1. Revenue and Profitability

Outstanding Nine-Month Revenue Growth
For the nine months ending September 30, 2024, iQSTEL's revenue skyrocketed to $184 million—nearly double last year's $97 million, reflecting a remarkable 89% increase. This powerful growth underscores strong market demand and our strategic expansion, especially in our Telecom Division, which remains our primary driver of profitability and success.

Ambitious Full-Year Revenue Target
Our goal for FY-2024 is $290 million in revenue. With a gap of $106 million remaining to reach this target, we are mobilizing every resource to close it. Historically, Q4 has been our strongest quarter, and with QXTEL leading our international business, we are confident we will achieve our projections and finish the year on a high note.

Robust Gross Profit Base
Our gross profit reflects our ability to grow efficiently and sustainably:

Nine Months: Gross profit surged to $5.6 million, up from $3 million in 2023.
Quarterly: Q3 gross profit doubled to $2 million, establishing a consistent quarterly profit foundation.
Our stable business platform now enables us to generate $2 million in gross profit per quarter, paving the way for further bottom-line improvements through consolidation and the migration to a unified telecom platform.

Notably, in FY-2024, our gross margin has shown consistent improvement, increasing from 2.68% in Q1 to 3.72% in Q3, a remarkable 39% increase within the year. This progress underscores our focus on efficiency and profitability as we scale.

Consolidated Operating Income

Nine Months: Our operating loss was $535,952, mainly due to QXTEL integration expenses.
Quarterly: In Q3, our operating loss narrowed to $56,553, bringing us closer to the profitability threshold. Our Telecom Division continues to be a robust profit engine, effectively covering the company's core expenses.
Telecom Division Profitability and Consolidation Strategy
Our Telecom Division generated $548,274 in profit for Q3, confirming its role as a steady revenue source. We've launched a consolidation strategy within this division, with potential important savings. Recent actions in Q4 with SwissLink and QGlobal SMS are completely aligned with this strategy, and we are planning to begin to show its effects as early as Q4 of this year.

2. Interest Expense

Interest expenses rose to $1.5 million for the nine months, primarily due to strategic debt used for growth. We remain committed to maintaining long-term shareholder value by absorbing these interest costs instead of opting for equity dilution. Our outstanding share count remains below 187 million shares, which represents an increase less than 9% versus Dec 31, 2023. Notably, our investors have recently demonstrated their support by extending the maturity of our convertible notes by 12 months, with all notes now set to mature in Q1 FY-2026.

3. Assets and Liabilities

Asset Growth: Total assets rose to $32.4 million, up from $22.2 million in 2023, bolstered by QXTEL goodwill and increased accounts receivable.
Liabilities: Current liabilities grew to $24.1 million, a level we are strategically managing to support continued growth.
4. Cash Flow and Liquidity

Our financing activities generated $6.2 million in cash over the nine months, supporting our acquisition and expansion strategies. We ended the quarter with a steady $2.1 million in cash, demonstrating effective liquidity management as we scale.

5. Stockholders' Equity and Nasdaq Uplisting Readiness

iQSTEL's stockholders' equity rose to $8.1 million, surpassing the minimum requirement of $5 million for a Nasdaq uplisting. We are in the final stages of selecting an investment bank to support us in this pivotal move. Our goal is to position iQSTEL as a $1 billion revenue company by 2027, and uplisting to Nasdaq is a crucial step toward achieving this vision.

6. Global Presence, Operational Reach, and branding

Our global reach now spans 100 employees across 20 countries and 17 time zones with six offices worldwide, providing 24/7 service from California to Melbourne. This global presence enables us to effectively serve clients around the world, reinforcing our position as a leading global player. As part of our Telecom Division's consolidation, we are optimizing our global network and operations to maximize efficiency.

The company has been collaborating with ONAR, a marketing agency, to develop a comprehensive branding strategy for iQSTEL. Management recognizes that achieving our vision of becoming a $1 billion revenue corporation requires establishing strong brand recognition as a cornerstone of our growth.

7. Innovation in High-Tech, High-Margin Products

High Margin Strategy: iQSTEL has built connections with some of the world's largest telecommunications companies, generating millions in annual revenue. With these robust relationships, we're poised to expand our offerings, focusing on high-tech, high-margin products.
Cybersecurity: We're collaborating with Cycurion.com to launch a telecom-targeted cybersecurity service in Q1 FY-2025.
AI Solutions: Our recent launch of AIRWEB.ai has exceeded expectations, attracting strong interest with its free plan and positioning us as a leader in AI-enhanced telecom services.
Summary

iQSTEL's financial and operational results for Q3 and the first nine months of 2024 reflect transformative growth and strategic expansion. With a profitable Telecom Division, a successful QXTEL acquisition, and a solid equity foundation, we are well-prepared for our Nasdaq uplisting, a long-awaited goal of our 22,000 shareholders.

Our newly established corporate financial planning department is set to work closely with our subsidiaries on a monthly basis, implementing a robust plan to drive bottom-line results starting in FY-2025. With a steadfast commitment from our Independent Board of Directors and strong investor support, iQSTEL is on an accelerated path to becoming a $1 billion revenue powerhouse by 2027.

The future is bright, and we are deeply grateful for your continued support and belief in our journey. Together, let's make this vision a reality.

Thank you for your continued support.

Sincerely,
Leandro Jose Iglesias
President & CEO, iQSTEL

About iQSTEL (Updated Oct. 2024):

iQSTEL Inc. (OTC-QX: IQST) (www.iQSTEL.com) is a US-based multinational publicly listed company in the final stages of the path to becoming listed on NASDAQ. With FY2023 revenues of $144 million and a forecasted $290 million in revenue, alongside positive operating income of seven digits for FY-2024, iQSTEL is positioning itself for explosive growth. iQSTEL's mission is to serve basic human needs in today's modern world by making essential tools accessible, regardless of race, ethnicity, religion, socioeconomic status, or identity. The company recognizes that modern human needs such as physiological, safety, relationship, esteem, and self-actualization are marginalized without access to ubiquitous communications, financial freedom, clean, affordable mobility, and information.

iQSTEL has been building a strong business platform with its customers, and by leveraging this trust, the company is now beginning to sell high-tech, high-margin products across its divisions. iQSTEL is strategically positioned to achieve $1 billion in revenue by 2027 through organic growth, acquisitions, and high-margin product expansion.

Telecommunications Services Division (Communications):
Includes VoIP, SMS, International Fiber-Optic, Proprietary Internet of Things (IoT), and a Proprietary Mobile Portability Blockchain Platform.
Fintech Division (Financial Freedom):
Provides remittance services, top-up services, a MasterCard Debit Card, US bank accounts (no SSN required), and a Mobile App.
Electric Vehicles (EV) Division (Mobility):
Offers Electric Motorcycles and plans to launch a Mid-Speed Car.
Artificial Intelligence (AI) Services Division (Information and Content):
Provides AI solutions for unified customer engagement across web and phone channels, along with a white-label platform offering seamless access to services, entertainment, and support in a virtual 3D interface.
Cybersecurity Services:
Through a new partnership with Cycurion, iQSTEL will offer advanced cybersecurity solutions, including 24/7 monitoring, threat detection, incident response, vulnerability assessments, and compliance management, providing essential protection to telecommunications clients and beyond.
iQSTEL has completed 11 acquisitions since June 2018 and continues to develop an active pipeline of potential future acquisitions, further expanding its suite of products and services both organically and through mergers and acquisitions.

Safe Harbor Statement: Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and iQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Company Website
http://www.iqstel.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/iqst---iqstel-releases-q3-fy-2024-shareholder-letter-highlighting-record-growth-strategic-expansion-and-nasdaq-uplisting-progress-302305478.html

SOURCE iQSTEL

[ProfitScout]

$PWM: Prestige Wealth Inc. Announces Acquisition of Tokyo Bay

HONG KONG, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Prestige Wealth Inc. (NASDAQ: PWM) (“PWM”, or the “Company”), a wealth management and asset management services provider based in Hong Kong, today announced that, on November 12, 2024, it entered into a definitive acquisition agreement pursuant to which PWM will purchase all shares of Tokyo Bay Management Inc. (“Tokyo Bay”), a company incorporated under the laws of the British Virgin Islands. The total purchase price is US$1,500,000, subject to customary closing purchase price adjustments, in the form of 2,500,000 newly issued Class B ordinary shares of the Company at a price per Class B ordinary share of US$0.60 to the seller and key employees of Tokyo Bay. The Company will also grant warrants to purchase 1,875,000 Class A ordinary shares of the Company at an exercise price per share equal to US$0.72 to the seller parties. The warrants will become exercisable on the six-month anniversary of the issuance date and will expire on the fifth anniversary from the date on which they become exercisable. In addition, key employees will be retained and continue to be employed by Tokyo Bay after closing of the transaction. The acquisition agreement also includes a third-year period non-competition and non-solicitation covenants from the seller parties. Upon consummation of the acquisition of Tokyo Bay, that certain business development & marketing agreement by and between PWM and Tokyo Bay dated as of June 24, 2024 will be terminated. The acquisition of Tokyo Bay is expected to close in the fourth quarter of 2024 and will enhance PWM’s strategy and development in Asia wealth management industry.

About Prestige Wealth Inc.

Prestige Wealth Inc. is a wealth management and asset management services provider based in Hong Kong, assisting its clients in identifying and purchasing well-matched wealth management products and global asset management products. With a focus on quality service, the Company has retained a loyal customer base consisting of high-net-worth and ultra-high-net-worth clients in Asia. Through the Company’s wealth management service, it introduces clients to customized wealth management products and provides them with tailored value-added services. The Company provides asset management services via investment funds that it manages and also provides discretionary account management services and asset management-related advisory services to clients. For more information, please visit the Company’s website: http://ir.prestigewm.hk.

About Tokyo Bay

Tokyo Bay is a company based in Tokyo, Japan. Founded by experienced professionals, the Tokyo Bay team has accumulated extensive premium client resources and local market knowledge over the past years, providing wealth management services, family affairs services, lifestyle management services and related value-added services to high-net-worth clients in Japan.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this press release. They include statements about the Company’s plans for the business of InnoSphere Tech and Tokyo Bay; anticipated financial and other results from the acquisition of InnoSphere Tech and Tokyo Bay and its integration into PWM; expectations regarding revenue and cost synergies resulting from the acquisition; discussion of other strategic initiatives and related actions; and beliefs, expectations, intentions and strategies, among other things. Forward-looking statements are based on management's current beliefs, expectations and assumptions, and involve a number of known and unknown risks and uncertainties, many of which are out of PWM’s control.

The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with U.S. Securities and Exchange Commission.

https://www.globenewswire.com/newsroom/ti?nf=OTI3MjExNiM2NTc4Mjk4IzIyNTQzNjg=
https://ml.globenewswire.com/media/M2Y4ZDE3ODUtOGMyYy00MDBmLWIzZGItNWE1YTBiMDcyNjBmLTEyNjU5MTc=/tiny/Prestige-Wealth-Inc-.png
For more information, please contact:

Prestige Wealth Inc.

Investor Relations Department

Email: [e-mail]
Source: Prestige Wealth Inc.

[Golden Cross]

$ILLR #Triller Group's transformation has begun with ambitious plans set by Bob diamond. Triller + AGBA Forging A New Path Ahead.

[Golden Cross]

$ILLR Triller Opens a New Frontier in the Digital Technology Space 🚀 Triller and @agbagroup are joining forces to create a $4 billion powerhouse in digital content and financial services. This groundbreaking merger combines Triller’s AI-driven content platform with AGBA’s financial expertise, aiming to redefine the convergence of technology, finance, and media.

[ProfitScout]

$BLIS News: NAPC Defense (OTCPK: BLIS) Awarded in Excess of $1 Million in Clean-up Contracts following Hurricanes Helene and Milton

The Company is Working on Additional Potential Restoration and Clean-up Contracts

LARGO, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announced today that the Company has received in excess of $1 million in new orders for support in the clean-up efforts from hurricanes Helene and Milton.

The work included in today’s contract is scheduled to be completed the next 60-90 days and is important part of restoring the communities in which the Company operates.

The Company has another $2 million in pending awards for additional construction and clean-up in the Tampa Bay area.

NAPC anticipates that this type of work will continue for at least 3 more years.

Kenny West, CEO of NAPC, stated, “The clean-up and rebuild of the Tampa Bay area, following these devastating storms, has left many people in need of our services and we are doing all we can to support our neighbors with quality services, as we have for 9 years. I thank our dedicated team members for rallying to help us in our mission to restore our community.”

About NAPC Defense, Inc.

NAPC Defense, Inc. (http://www.napcdefense.com) is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S. and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.

FORWARD LOOKING STATEMENTS:

This press release and the statements of representatives of NAPC. (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.

These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.

COMPANY CONTACT:

Kenny West, CEO [phone] Ext.713

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a1879197-c710-4e04-bf9d-eb5c83d5e5d5https://www.globenewswire.com/NewsRoom/AttachmentNg/6a2d8fbd-10e0-46a3-810b-1f6aa1bdff2ehttps://www.globenewswire.com/NewsRoom/AttachmentNg/07a766d4-5c91-4dbc-b69b-fc26e63225d7https://www.globenewswire.com/NewsRoom/AttachmentNg/3277c3ec-88ed-42f2-929b-084d919fe354

https://www.globenewswire.com/newsroom/ti?nf=OTI2MTA4NSM2NTQ3MDMyIzIyNjE1MDY=
https://ml.globenewswire.com/media/YTI0ODkwMDgtNTY3ZC00MDM1LTk2MGItZDhkZmYzNDI5NDQ4LTEyNzMwNTY=/tiny/NAPC-Defense-Inc-.png


Source: NAPC Defense, Inc.

[Golden Cross]

$ILLR Triller The New #TikTok Alternative ~ $40/Share!

[ProfitScout]

$NAHD News: New Asia Holdings Inc (NAHD) Announces Shareholder Update

Electra, Oct. 23, 2024 (GLOBE NEWSWIRE) -- New Asia Holdings Inc./Olenox Corp. (NAHD” or the Company) (OTCQB: NAHD), announces a shareholder update.

Corporate Developments

The company continues to work on its consolidated audited financials and expects to be completed and filed by the end of November and is on target to complete and file them by then.

New Asia has also been working in the background with its capital stock to meet the OTC market requirement of a 10% public float by reducing the outstanding shares. The company was removed from OTCQB in mid-August for not having 10% of its stock in the public float. The company now meets those requirements and currently has 12.7 percent of its outstanding shares in the float.

Olenox is a fully integrated energy company that produces responsible energy products both traditional and renewable. Our continued focus on carbon footprint reduction and streamlined oil and gas production not only benefits the environment and local communities but also add value to Olenox bottom line.

The company continues as well to work towards our green initiative to produce carbon-neutral products as well as integrate solar and other renewable technologies into our daily oil and gas production operations.

Acquisitions



On August 13th, 2024, New Asia announced it had purchased 162 miles of Texas pipeline from Taylor Consulting. The company is currently looking to bring the pipeline back into production and working with the anchor customer to renew takeoff agreements. An existing agreement is in place for 55,000 MCF per month and the company is looking at several other projects that could be attached to the pipeline including power generation and bitcoin mining operations.

On August 8th, 2024, New Asia/Olenox announced that its wholly owned Olenox Kansas has been selected to operate 181 natural gas wells in the Bradshaw portion of the Giant Hugoton Field in Kansas. The company continues to bring on production and is working towards the goal of having half the field in production by Q1 2025. The company to date has brought back 32 wells into production and is now working on abandoning 3 wells to meet the contract requirements for the year.

New Asia/Olenox continues to work on several other acquisitions and is in the final stages of purchase negotiations with 2 of the 4 currently under consideration.

Technology

Olenox continues to develop its technologies and is pushing its downhole tooling forward. Modifications were needed for both the Plasma pulse tool and the ultra-sonic tool to meet industry standards in Texas and the company will begin to use the technology in our field in the coming months.

About Olenox Corp.
Olenox Corp.is a diversified energy company based in the state of Texas that currently operates three vertically integrated business units – Oil and Gas, Energy Services and Energy Technologies.

Oil and Gas: focuses on acquiring and optimizing underdeveloped oil and gas assets in Texas, Kansas and Oklahoma. It employs both internally developed and third party-licensed technologies to increase production, optimize performance and reduce costs. Olenox currently operates several oil and gas properties in Texas and Kansas.
Energy Services: This business unit supports Olenox’s overall exploration and production efforts with “well services” and “end of life reclamation.” Olenox Energy Services owns and operates a combination of customized service-wireline rigs and HydroVac units. This specialized equipment allows for faster “rig in” and “rig out” times. Overall, Olenox Energy Services’ equipment and experience combination seeks to reduce the amount of time and fuel burned to complete an abandonment or workover thus reducing costs.
Energy Technologies: This business provides both R&D and existing technology to enable increased production in the field. Olenox flagship intellectual property is its downhole enhanced recovery plasma pulse tooling and ultrasonic cleaning tools.
Each of Olenox’s three vertically integrated business units operate in tandem to help Olenox capture unique opportunities that often go untapped by the Company's competitors.

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.



For more information, please contact:
Olenox Corp.
205S Bailey Street, Electra, Texas 76360
Email: [e-mail]
Phone: [phone]

Facebook: https://www.facebook.com/OlenoxCorp
Instagram: https://www.instagram.com/olenoxcorp/
Twitter: https://x.com/OlenoxCorp
YouTube: https://www.youtube.com/@OlenoxCorp
Linkedin: https://www.linkedin.com/company/olenoxcorp/

[ProfitScout]

$RENB News: RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.

This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping.

“The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations (CNAs), which characterize the copy number landscape of lung cancer tissues—traditionally assessed through tissue biopsy,” said Khashayar Roohollahi, senior scientist at RenovaroCube.

Furthermore, CNAs can be used to estimate tumor fractions which is useful for predicting cancer progression and monitoring. The study emphasizes the potential of this technology in reducing the need for invasive tissue biopsies, a significant advancement in oncology.

Read more about the poster: https://renovarogroup.com/novel-insights-on-non-invasive-cancer-diagnostics-poster/

RenovaroCube remains committed to advancing precision medicine through innovative research and technologies, offering hope for more effective, patient-centered cancer care.

About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments utilizing non-invasive liquid biobsy. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

About MAP
MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: [e-mail] and [e-mail]

Source: Renovaro Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTI1Nzg5NiM2NTM3ODEwIzIxMjA2Nzk=
https://ml.globenewswire.com/media/N2ExZjNkNDktODBhZC00MGRlLWE4OWItNjY5MWQ1ODYwOWNiLTExMzIyNTA=/tiny/Renovaro-Inc.png

Source: Renovaro Inc

[Golden Cross]

$AGBA + TRILLER ~ MEGA 4B MERGER COMPLED. Statement on future leadership, strategy and objectives on Tuesday, October 22, 2024.💎💯

[Golden Cross]

💲 $AGBA $4 Billion Merger With Triller..... The Next Big Social Media Platform Ready To Take On META/Facebook and TikTok 💪

Merger closes this next Monday(10/14) after the close...

[ProfitScout]

$CETX News: Cemtrex’s Advanced Industrial Services Secures $4.5 million Contract

Two Phase Project be Completed in the Company’s Fiscal Year 2025

Brooklyn, NY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today announced it has received a $4.5 million contract through its Advanced Industrial Services (“AIS”) subsidiary underscoring the Company’s strong market position and optimistic growth outlook. The contract award is for both Phase 1 and Phase 2 of the Department of General Services’ Elizabethtown Training Academy project.

Phase 1 of the project involves the complete renovation of the HVAC systems at the academy, while Phase 2 will focus on the renovation of the Boiler Plant and the Domestic/Fire Protection piping. These updates are expected to significantly enhance the facility’s energy efficiency, safety, and operational capabilities. The project is expected to be completed in the Company’s Fiscal Year 2025.

“This contract award reaffirms AIS’s optimistic growth outlook,” said Saagar Govil, Chairman and CEO of Cemtrex. “The company’s ability to secure this project is a direct result of the strategic acquisition, Heisey Mechanical, completed in 2023, which has expanded AIS’s capacity and capabilities. We are now beginning to see the benefits of that transaction, with contract awards like this one marking the early returns. AIS sees continued opportunity to pursue and expand into similar large-scale infrastructure projects in the future. We also continue to explore additional acquisition opportunities that can build on and accelerate our growth further.”

About Cemtrex

Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.

Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit www.vicon-security.com

AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com

For more information visit http://www.cemtrex.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.

https://www.globenewswire.com/newsroom/ti?nf=OTI0OTI3MCM2NTEzMzI3IzIwNDk3MDg=
https://ml.globenewswire.com/media/N2JiMjM3Y2YtODk2MS00MWJhLThlYzQtNzhhOGM4OTk2NzI4LTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235

[e-mail]
www.mzgroup.us

Source: Cemtrex Inc.

[ProfitScout]

$GNPX News: Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma

AUSTIN, Texas, Sept. 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024 in Barcelona, Spain. The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.

"We are very pleased that these studies with our academic partners have been selected for presentation, which expands the growing body of preclinical evidence supporting REQORSA's potential to treat a variety of cancers," said Ryan Confer, President and Chief Executive Officer at Genprex. "We look forward to these presentations next month which will share the compelling data that support the potential for new clinical studies evaluating Reqorsa as a potential treatment for additional types of lung cancer, mesothelioma and glioblastoma."

Featured Genprex-supported posters to be presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics include:

Title: "TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib"
Collaborator: The University of Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372

Title: "TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells"
Collaborator: New York University Langone Health
Catalog Number: 364
Presentation Number: PB352

Title: "Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene Therapy in Glioblastoma"
Collaborator: The University of Texas Health Science Center at Houston
Catalog Number: 130
Presentation Number: PB118

Genprex has filed two provisional patent applications based on data from two of the presentations. One application involves using REQORSA to treat mesothelioma and the other to treating glioblastoma. Genprex is a co-owner of the applications along with the respective institutions. TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]

https://c212.net/c/img/favicon.png?sn=DA00335&sd=2024-09-09 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-302241636.html

SOURCE Genprex, Inc.

[ProfitScout]

$GNPX News: Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program

New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes

AUSTIN, Texas, Sept. 4, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D).

"Genprex's diabetes program has received the attention of several potential investors, partners, collaborators and pharmaceutical companies, and we believe separating it from our oncology programs could help increase interest, expedite clinical development and unlock the value of our novel diabetes program," said Ryan Confer, President and Chief Executive Officer at Genprex. "The new subsidiary would be positioned to be a pure-play diabetes-focused biopharmaceutical company, while Genprex would be a pure-play oncology-focused biopharmaceutical company. This contemplated separation of entities could enable potential direct investment and strategic collaboration into the advancement of the diabetes program. Diabetic patients are in need of advanced therapies, and we believe GPX-002 holds the potential for disease modification for long-term effectiveness, which could directly impact the global diabetes epidemic."

The planned spin-out transaction would allow both Genprex and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The spin-out, if completed as presently contemplated, would result in NewCo focusing on developing GPX-002, while Genprex would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates Genprex's strong ongoing commitment to the Company's streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024, subject to adequate financing, the satisfaction of customary conditions and final approval from the Genprex management and Board of Directors.

The Company's goal for separating the diabetes clinical development program from its oncology program follows closely behind Genprex's recent announcement to re-focus its oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, the Company continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, the Company is considering various strategic alternatives and opportunities to enhance stockholder value.

GPX-002, which has been exclusively licensed from the University of Pittsburgh, is being developed using the same construct for the treatment of both T1D and T2D. The same general novel approach is used in each of T1D and T2D whereby an adeno-associated virus (AAV) vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. The diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh.

"With the potential to address the entire diabetes market, we believe our gene therapy approach would position NewCo as an innovator in emerging diabetes therapies," continued Confer. "The most significant advancement in the treatment of diabetes happened more than 100 years ago when insulin was first introduced to treat T1D patients. We believe our treatment has the potential to disrupt the diabetes market by replacing the daily burden of blood glucose monitoring and insulin replacement therapy, as well as the need for GLP-1 treatments in T2D."

About GPX-002 and Diabetes

In T1D, GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In vivo, preclinical studies show that GPX-002 restored normal blood glucose levels for an extended period of time.

In February 2023, research collaborators at the University of Pittsburgh presented preclinical data in a NHP model of Type 1 diabetes highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin, Germany.

The statistically significant study results showed the treated animals had:

Decreased insulin requirements
Increased c-peptide levels
Improved glucose tolerance compared to baseline
In April 2023, Genprex hosted a Key Opinion Leader virtual event entitled "Novel Gene Therapy to Treat Type 1 Diabetes," which discussed preclinical data reported at ATTD 2023 supporting gene therapy to treat T1D. Watch the KOL event here.

In a similar approach for T2D, GPX-002 (formerly known as GPX-003), where autoimmunity is not at play, is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.

According to the U.S. Center for Disease Control as of 2024, 38.4 million Americans, or approximately 11.6% of the U.S. population, have diabetes. It is also believed that more than 97 million Americans aged 18 years or older have prediabetes. In 2021, approximately 537 million adults (20-79 years) worldwide were living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million in 2045. Also in 2021, diabetes caused more than 6.7 million deaths globally and diabetes resulted in approximately $966 billion dollars in health expenditures, a 316% increase over the preceding fifteen years.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the potential separation of its diabetes clinical development program, including the anticipated benefits of the internal reorganization, the expected timing of the reorganization and/or if it is completed as contemplated or at all; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its short-term and long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]


https://c212.net/c/img/favicon.png?sn=DA97213&sd=2024-09-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-plans-to-launch-separate-company-to-focus-on-the-development-of-gene-therapy-to-treat-type-1-and-type-2-diabetes-302237871.html

SOURCE Genprex, Inc.

[ProfitScout]

$GNPX: Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes

Video Highlights Recent Oncology Clinical Development Program Updates

AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company's oncology clinical development program.

The Acclaim-1 clinical trial is evaluating the combination of the Company's lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.

The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Dr. Berger remarked on the two positive patient outcomes in Acclaim-1:
"Both of these patients' outcomes are fairly remarkable in terms of their prolonged Progression Free Survival (PFS) among patients in the study who were progressing on their previous treatment when they came into the study. It's very compelling, particularly, that one of those patients has maintained this benefit for more than two years. And over time, the patients' side effects with the combination of REQORSA and Tagrisso have diminished rather than increased over time."

Dr. Berger's commentary on the positive patient outcome in Acclaim-3:
"In the Acclaim-3 study, the first patient treated in the Phase 1 dose escalation portion of the trial has had a positive response since enrollment and starting maintenance therapy. The patient has a partial remission (PR) from the start of maintenance therapy until after the second course, which is when the first CT scan is done. This is the first dose group in this study, and there is a second higher dose group to come. The patient's response is remarkable, and it is very unusual to have a PR during maintenance therapy. We believe these results bode very well for the study."

On recent updates to the Company's oncology clinical development program, Dr. Berger stated:
"To build on these positive patient results, we are making changes to our clinical development program both in the Acclaim-1 and Acclaim-2 studies. In the Acclaim-1 study, we are removing one of the cohorts in Phase 2a, which will allow us to advance more quickly. The Acclaim-2 study is being closed to further enrollment. It has been slow to enroll patients, mainly because there are hundreds of other very similar studies that evaluate new treatments after patients have progressed on Keytruda®. We certainly intend to continue to treat patients in this study until they have disease progression. We also believe closing to further enrollment is the right thing to do so that we can focus our limited resources on the fastest way to being able to enroll patients and get clinical data.

We're very excited by these positive patient responses, and we look forward to advancing REQORSA through the clinic. We believe that streamlining our efforts to do so is the best way to use our resources and to move our program forward."

To watch the video, please visit Genprex's website at https://www.genprex.com/videos/.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the initial patient responses to REQORSA treatments and the potential and promise of these responses, which are demonstrating early evidence of efficacy with a favorable safety profile; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]

https://c212.net/c/img/favicon.png?sn=DA84592&sd=2024-08-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-outcomes-in-two-lung-cancer-clinical-trials-302223226.html

SOURCE Genprex, Inc.

[ProfitScout]

$BIVI: BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

Presentation to showcase potential impact of bezisterim on biological age, gene expression and measures of aging-related diseases from growing body of clinical evidence

CARSON CITY, Nev., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster presentation will be shared at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) being held August 26-30, 2024 in Copenhagen, Denmark.

The presentation “Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments” will provide an overview of clinical data to-date on bezisterim, focusing on various analyses and measurements related to longevity and its ability to affect the biological aging process. The presentation will be given by Christopher L. Reading, BioVie’s Senior Vice President, Alzheimer’s Disease Program, on Tuesday, August 27 from 14:40 - 15:00 CEST.

Details of the presented data and conclusions will be announced once the presentation is made public at the conference.

About Bezisterim
Bezisterim (NE3107) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-to-drug interaction. Bezisterim has the potential to reduce symptoms of long COVID, including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFkB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). NE3107 has been shown to modulate the activation of NFkB and thus modulate inflammation.

Bezisterim is being investigated for Alzheimer’s disease (AD) and Parkinson’s disease (PD). BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from AD. A Phase 2 study of bezisterim in PD (NCT05083260) has been completed, and data presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events.

About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration (“FDA”) Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com.

Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. In this press release, forward-looking statements include, but are not limited to, the potential impact of bezisterim on cognition and function among study participants and topline data from the bezisterim trial. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries:

Contact:
Bruce MackleManaging Director LifeSci Advisors, LLC
[e-mail]

For Media Inquires
Melyssa Weible
Managing Partner, Elixir Health Public Relations
Ph: [phone]
[e-mail]

https://www.globenewswire.com/newsroom/ti?nf=OTIwMzY0MiM2NDIwNjE4IzUwMDA3OTY2Ng==
https://ml.globenewswire.com/media/NmVhZjI2ZjAtNjg1OC00MzdlLTkzY2QtMWRhYmYwOTE5NzgzLTUwMDA3OTY2Ng==/tiny/BioVie-Inc-.png

Source: BioVie, Inc.

[ProfitScout]

$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content

First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content

JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.

The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.

"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.

Key Findings:

Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.

Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."

For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.

About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.

About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com

Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html

SOURCE Safety Shot

[ProfitScout]

$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.

This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

[ProfitScout]

$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market

Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership

LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.

A Strategic Move in Response to Growing Demand

This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.

Quote from Mike Elliott, VP of Business Development

"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."

Expanding CyttaAIR's Reach

This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.

About Cytta Corp:

Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.

The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.

About FIZUAS Unmanned Aircraft Systems

FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.

Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
[e-mail]
Direct: (516)-455-7662

Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
[e-mail]

Gary Campbell, CEO
Direct [phone] (or message)
[e-mail]

Mike Elliott, VP of Business Development
[e-mail]
[phone]

SOURCE: Cytta Corp.
https://finance.yahoo.com/news/cyttaair-partners-fizuas-dominate-american-120000070.html

[ProfitScout]

$SHOT: Wellness And Dietary Supplement Company Safety Shot Reports Bringing World's First Patented Rapid Blood Alcohol Detox Solution To Market - Safety Shot (NASDAQ:SHOT) - Benzinga
Click here:
https://www.benzinga.com/partner/emerging-markets/24/06/39361121/wellness-and-dietary-supplement-company-safety-shot-reports-bringing-worlds-first-patent

[ProfitScout]

$ACGX #PeopleVine keeps Growing! Join us at the #OracleRestaurantsSummit this week in Miami https://peoplevine.com #PrivateMembership #MembershipClubs #MemberPayments #GlobalProfile #CRM $ACGXhttps://x.com/ACGpaul/status/1800534182638297227

[ProfitScout]

$ACGX is a true value play on the OTC: Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024

West Devon Property listed for sale at $3.950,000 with a 7.97% Cap Rate

CHICAGO, May 15, 2024 /PRNewswire/ -- Alliance Creative Group, Inc., (http://www.ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Quarter Ending March 31, 2024.

Revenues for the Quarter ending March 31, 2024 ("Q1 2024") were $217,916 Gross Profits for the Quarter ending March 31, 2024 ("Q1 2024") were $217,916 Net Income for the Quarter ending March 31, 2024 ("Q1 2024") were $142,330

The total assets on the Balance Sheet for the Alliance Creative Group as of 3/31/24 were $4,531,689

The total outstanding common shares as of March 31, 2024 were 4,454,211 with 2,799,023 of those shares in the float - Same as the end of the third quarter.

The Company ended the quarter with $156,554 Cash on hand.

The property located at 1324 W. Devon Ave, Chicago, IL. 60660 has been listed for sale at $3,950,000 ($246,975 per Unit) with a 7.97% Cap Rate - Link below:

https://www.loopnet.com/Listing/1324-W-Devon-Ave-Chicago-IL/31610262/

The full financial statement, balance sheet, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on www.ACGX,us in the investor relations section.

Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "This quarter was a continuation of keeping our expenses as low as possible while we attempt to sell the 1324 W. Devon property and look for the next best strategic investment, acquisition, or partnership to continue to grow our positive cashflow and position ourselves for potentially larger opportunities.

PeopleVine had another strong quarter and we are engaging in multiple conversations to determine the best next steps for us.

Overall we are in search of a potential strategic acquisition or project that can leverage our foundation to grow and scale faster than on their own. We will continue to update the public as things progress and will share more details as they become available."

About Alliance Creative Group, Inc.

Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit www.AllianceCreativeGroup.com or www.ACGX.us.

About PeopleVine

PeopleVine is a Software as a Service (SAAS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.

For more information www.PeopleVine.com

About Say Less Spritz

Say Less Spritz is a low ABV premium light wine in a can. Say Less blends a carefully sourced selection of West Coast rosé and wine varietals with sparkling water and real fruit juice to create a single serving ready to drink (RTD) wine in a can. The Award winning Products come in 6 flavors: Classic Rosé Spritz, Pineapple Rosé Spritz, Watermelon Rosé Spritz, Pinot Noir, Chardonnay, and Sauvignon Blanc. All products are 100 calories or less, 5 grams of sugar or less, and contain all natural ingredients. The rosé collection is sweetened with monk fruit to provide a cleaner and more enjoyable drinking experience without compromising on taste or quality. Currently, Products can be found in over a dozen states and in over 1,000 stores. Some retailers include: HEB, Jewel Osco, Meijer, Liquor Barn, and lots more, as well as GoPuff and SpiritHub online. Product can also be found in iconic venues such as Wrigley Field, The Grand Ol' Opry, and The Philadelphia Zoo, where the brand continues to captivate wine enthusiasts who are looking for a refreshing and convenient beverage choice.

This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more info: www.SayLessSpritz.com
Investor Relations and Media Contact
1-312-498-9769; [e-mail]

Cision View original content:https://www.prnewswire.com/news-releases/alliance-creative-group-acgx-releases-q1-2024-financial-and-disclosure-report-with-an-88-increase-in-net-income-from-q1-2023-to-q1-2024-302146296.html

SOURCE Alliance Creative Group, Inc.

[QuicKtip]

$RWGI is proud to announce a significant strategic move including signing a Letter of Intent (LOI) for the dispensary's license acquisition, further solidifying RWGI's presence in the burgeoning cannabis market. https://finance.yahoo.com/news/rodedawg-otc-rwgi-expands-dispensary-120000919.html

[QuicKtip]

$CBDW is pleased to invite investors to a webinar on June 11, 2024, at 4:15 p.m. ET. https://finance.yahoo.com/news/1606-corp-host-exclusive-live-120000020.html

[ProfitScout]

$IVDN News on sales surge for superior, energy saving house wrap: Innovative Designs Sales Update

PITTSBURGH, PA- (NewMediaWire) - May 30, 2024 - Innovative Designs, Inc. (OTCQB: IVDN) continues its upward sales trend into the end of May 2024. Year-to-date sales have already surpassed FYE2023 by over 33% with 5 months remaining in FYE2024. The growth is attributed to a substantial increase in the number of new retailers that are now carrying the company's Insultex House Wrap®. As new energy codes are implemented across the United States, homebuilders/contractors are using Insultex House Wrap® as a convenient R-Value continuous insulation to a wall system.

Our notable growth in sales can be attributed to Built Link Solutions (Formerly Compound Construction) based in Grand Rapids, MI. Built Link Solutions is working to become the primary source for industry professionals, innovators, and stakeholders to discover, evaluate, and adopt the latest advancements in building materials, tools and technologies. Having curated a comprehensive national distribution network, they bring pioneering solutions like Insultex House Wrap® to market, propelling the evolution of the construction industry towards a future where innovation thrives, and buildings meet the needs of tomorrow. Since coming onboard, Built Link Solutions has:

Established a comprehensive national distribution network to service customers where they are when they need it.

Grown national awareness of product benefits and specifications through their dedicated sales agents and attendance at building industry trade shows across the country.

Conducted in-person sales training and online seminars to educate sales associates on Insultex House Wrap®.

Streamlined the sales process to deliver consistent and superior level service to customers of all sizes and needs.

Implemented volume pricing models and incentive discounts to meet the needs for scale and demand.

As building codes and exterior R-Value requirements are quickly evolving across the country, Built Link Solutions has proven highly proactive in contacting prospective accounts, notifying them of the cost-effective solution that our Insultex House Wrap® provides.

Randy Kimbler, Director of Business Development for Built Link Solutions, commented, "Insultex House Wrap® is gaining traction in the market as it provides a timely and effective solution. Its cost-effectiveness, innovation, and ability to address today's building challenges are driving positive feedback nationwide."

About Innovative Designs, Inc.

Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest, and warmest insulator in the market today. For more information, please visit:
http://www.idigear.comorhttp://www.insultexhousewrap.com.

Disclaimer

Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available athttp://www.sec.gov.

CONTACT:

Innovative Designs, Inc.

Joseph Riccelli, CEO

412-799-0350
[e-mail]

http://www.insultexhousewrap.com

Built Link Solutions

Randy Kimbler, Dir. Business Development

616-443-3200

[e-mail]

News Source: Innovative Designs Inc

[ProfitScout]

$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: [phone]
E: [e-mail]

[ProfitScout]

$GV News: GV Digital Technology Building

TORONTO, May 20, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced on May 19, 2024, a signing ceremony was held at Visionary Tower in Toronto. Visionary Holding Group's CEO, Mr. Zhong Chen, and Simon Tang, Director of ABB-FG from the United States, signed a cooperation agreement. Both parties will collaborate to transform and upgrade Visionary's two buildings located at 95-105 Moatfield Dr, Toronto, Ontario into the "GV Digital Technology Building."

ABB-FG will use cutting-edge digital technology and specialized securitization laws to register various real-world assets (RWA) with the U.S. Securities and Exchange Commission under Reg. D/S/A+. These assets will be supported by the most reliable public blockchain and token platforms and will be listed for uninterrupted trading on major global digital asset exchanges (ATS). After digitizing and securitizing the properties at 95-105 Moatfield Dr, ABB-FG will facilitate their global trading on ATS, significantly enhancing the value of these properties. This will also rapidly boost Visionary's own economic growth, advancing Visionary's industries toward internet-based, digital, and intelligent operations. The transformation will reduce operational costs, improve user experience, and increase industry revenue, positioning Visionary as a pioneer in Canada's digital economy.

Additionally, Visionary plans to apply for planning approval from the City of Toronto to develop the vacant land at 95-105 Moatfield Dr. The plan includes the construction of three additional buildings, creating a digital technology complex with a total building area of 1.5 million square feet, seamlessly integrating five buildings with complementary functions. This project aims to establish a landmark for Toronto's digital economy, contributing to the development of new models for digital economic growth and industrial upgrading in Canada.

In the context of the Fourth Industrial Revolution, digital technology will reshape the global economic and industrial landscape, becoming a strategic high ground for competition among nations and enterprises. It is a crucial engine for global economic development and a key accelerator for innovation breakthroughs in fields such as biotechnology, energy, new materials, and artificial intelligence. Visionary's future will focus on three core industries: biotechnology, new energy, and anti-aging products. We believe that the transformation and upgrading of these real estate properties will have a significant impact on the development of Visionary's three core industries.

About Visionary Holdings Inc.

Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
Email: [e-mail]

https://c212.net/c/img/favicon.png?sn=CN18297&sd=2024-05-20 View original content:https://www.prnewswire.com/news-releases/gv-digital-technology-building-302149815.html

SOURCE Visionary Holdings Inc.

[ProfitScout]

$NCL News: Northann Corp. Announces Strategic Partnership with Adornus Cabinetry

ELK GROVE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leader 3D printing home improvement solutions, today announced a strategic partnership with Adornus Cabinetry, a South Carolina-based manufacturer of luxury cabinetry. The partnership will focus on combining Northann’s pioneering 3D printing technologies with Adornus’ expertise in high-quality cabinetry design and manufacturing.

This synergy, said Northann, is expected to drive new innovations in materials and design processes, leading to the manufacture of cutting-edge, sustainable cabinetry solutions that are both beautiful and functional.

Other key elements of the partnership include:

Innovation in Product Development: Northann’s 3D printing ecosystem capabilities will imbue the new line of custom cabinetry with enhanced durability, customization, and quicker production times.

Sustainability Initiatives: As both companies are committed to sustainable practices, the partnership will focus on utilizing eco-friendly materials and processes.

Economic Impact: The collaboration is set to bolster the local economy by creating jobs and utilizing local resources in South Carolina.

"We are thrilled to partner with Adornus Cabinetry,” said Northann CEO Lin Li. “This collaboration marks a significant step forward in our company’s commitment to enhancing the integration of innovative solutions in the housing and construction industries.

"This partnership also signifies our dedication to supporting American industries and economies."

Mr. Lin said the partnership is expected to commence with a series of collaborative projects in Q3 of 2024, with further details to be announced shortly.

About Northann Corp.

Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.

For more information about Northann, please visit http://www.northann.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

Investor Relations
Northann Corp.
Email: [e-mail]
Phone: [phone]

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: [phone] x2
Email: [e-mail]

[ProfitScout]

$NCL News: Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product Wins Multiple Prestigious Awards in 2024

ELK GROVE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leader in innovative sustainable solutions, today announced that its Blue11-Ocean Plastic Flooring and Wall Panels Product has been recognized this year with industry awards for outstanding design, commitment to sustainability, and impeccable craftsmanship.
These awards include:

American Good Design Award 2024

French Design Award 2024

IDA Design Awards 2024

New York Product Design Awards

Green Product Award

Best Surfaces in TISE 2024

"We are truly honored to receive these prestigious awards, which underscore our commitment to creating products that are not only visually captivating but also environmentally conscious," remarked Northann Corp. CEO Lin Li. "This recognition fuels our passion to continue delivering innovative and sustainable solutions that resonate with our customers and contribute positively to the environment.

“Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product stands as a shining example of our company's enduring pursuit of excellence and sustainability.”

To learn more about this award-winning product and Northann Corp.'s comprehensive range of sustainable solutions, please visit www.northann.com and www.benchwick.com.

About Northann Corp.

Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.

For more information about Northann, please visit http://www.northann.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

Investor Relations
Northann Corp.
Email: [e-mail]
Phone: [phone]

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: [phone] x2
Email: [e-mail]

[Golden Cross]

$AGBA AGBA Group: Triller Merger Creates Significant Speculative Upside If TikTok Gets Banned In The U.S.
https://seekingalpha.com/article/4685179-agba-group-triller-merger-creates-significant-speculative-upside-if-tiktok-gets-banned-in-the-us

[ProfitScout]

$NCL News: Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products

ELK GROVE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Northann Corp (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce the signing of a strategic relationship with Golden Gate BCE B.V., a subsidiary of Rexil Group of Companies Netherlands, a prominent distributor in the Netherlands. This collaboration aims to enhance the presence of sustainable technology and products throughout Rexil Group of Companies Netherlands and its subsidiaries distribution channels.

Under this agreement, Rexil Group of Companies Netherlands will promote Northann Corp's environmentally friendly products, Blue11 and SuperOak, to its extensive network of customers in the Netherlands. This partnership aligns with Northann Corp's commitment to sustainability and innovation, furthering its mission to transform spaces through cutting-edge solutions.

"We are thrilled to partner with Rexil Group of Companies Netherlands to bring our sustainable technology and products to a wider audience in the Netherlands," said Lin Li, CEO and President of Northann Corp. "This collaboration underscores our dedication to environmental stewardship and showcases our commitment to providing innovative solutions to our customers."

Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.

About Northann Corp.

Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.

For more information about Northann, please visit www.northann.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

Investor Relations
Northann Corp.
Email: [e-mail]
Phone: [phone]

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: [phone] x2
Email: [e-mail]

https://www.globenewswire.com/newsroom/ti?nf=OTEwNDg4NiM2MjE2NTUyIzIyNTM4NDA=
https://ml.globenewswire.com/media/MjQ2NTdjZDQtMDFkMS00NjI4LWE0MTEtZDZkOTEzYjA1ZDkzLTEyNjUzOTM=/tiny/Northann-Corp-.png

Source: Northann Corp.

[ProfitScout]

$NCL News: Northann Corp.'s Benchwick Brand to Showcase SuperOak Hybrid Wood Planks Alongside Blue11 Collection at NWFA in New Orleans, April 16-18, 2024

ELK GROVE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL) today announced that its Benchwick brand will unveil its latest patented innovation, SuperOak Hybrid Wood Planks, before showcasing its award-winning Blue11 Collection, at the National Wood Flooring Association (NWFA) Expo in New Orleans, April 16-18, 2024, at the New Orleans Ernest N. Morial Convention Center - Hall F & G.

Combining the natural beauty of wood with the durability and sustainability of modern materials, SuperOak Hybrid Wood Planks represent a breakthrough in flooring technology. The product will be in stock across the U.S. starting in May, ensuring customers have access to this revolutionary flooring solution.

"We are thrilled to introduce our Benchwick SuperOak Hybrid Wood Planks, as well as showcase our award-winning Blue11 Collection, at NWFA," said Lin Li, CEO and President of Northann Corp. "SuperOak demonstrates our dedication to pushing the boundaries of flooring technology."

Attendees of NWFA are invited to visit Northann at booth number 2219 to explore the SuperOak and Blue11 Collection and learn more about Benchwick's cutting-edge flooring solutions.

For more information about Northann Corp. and its Benchwick brand, visit www.northann.com.

About Northann Corp.

Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.

For more information about Northann, please visit www.northann.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

Investor Relations
Northann Corp.
Email: [e-mail]
Phone: [phone]

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: [phone] x2
Email: [e-mail]

https://www.globenewswire.com/newsroom/ti?nf=OTA4OTg3MCM2MjAyMzk1IzIyNTM4NDA=
https://ml.globenewswire.com/media/ZWViZDNhYWYtNmMzYS00OGZiLTlmNjItMGI4MTE3NDQ2MTEyLTEyNjUzOTM=/tiny/Northann-Corp-.png

Source: Northann Corp.

[QuicKtip]

1847 Holdings LLC (NASDAQ: EFSH) Looking Primed for a Bounce

Float approx. 5.92m
Current PPS $2.03
https://mailchi.mp/broadstreetalerts/efsh-breakout-alert-95653?e=

[QuicKtip]

CSE: $TRUE, OTC: $TREIF THE NEXT BIG A.I. HEALTHCARE DISCOVERY
https://www.thebullreport.com/true/

[deri21]

$GEVI General Enterprise Ventures, Inc. (OTC:GEVI), Subsidiary Mighty Fire Breaker (MFB) Has Published Its Wildfire Defense System Course approved by the AIA and USGB Council through AEC Daily Corporation for Continuing Education Credits
https://finance.yahoo.com/news/general-enterprise-ventures-inc-otc-130000212.html

[ProfitScout]

$IVDN: We are working with an increasing number of customers to supply our R-6 rated Insultex House Wrap (TM) that advances the green building goal of higher energy efficiency. A patented evacuated cell design far outperforms all competition. Visit: http://insultexhousewrap.com
https://twitter.com/riccelli_joseph/status/1773147558660977070

[ProfitScout]

$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
Feb. 13th News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html

[ProfitScout]

$GVH News: Globavend Holdings Limited Enters Into a US$20,000,000 Equity Line of Credit Facility to be Registered on Form F-1

PERTH, AUSTRALIA, March 18, 2024 (GLOBE NEWSWIRE) -- Globavend Holdings Limited (Nasdaq: GVH) (the “Company” or “Globavend”), an emerging e-commerce logistics provider, is pleased to announce that it has entered into a US$20,000,000 equity purchase agreement (the “Equity Purchase Agreement”) with Square Gate Capital Master Fund, LLC – Series 1 (“Square Gate”), as well as a registration rights agreement (“Registration Right Agreement”) related thereto. Pursuant to the terms of the Registration Rights Agreement, the Company will register the Company’s ordinary shares (the “Shares”) issuable to Square Gate under the Equity Purchase Agreement for public resale.

Globavend will have the right, but not the obligation, to sell to Square Gate up to US$20,000,000 worth of its Shares at Globavend’s sole discretion over the next 36 months, subject to certain conditions precedent and other limitations. Square Gate will have the obligation to purchase the Shares a price determined in accordance with certain formulas set forth in the Equity Purchase Agreement and subject to certain dollar caps.

Wai Yiu Yau, CEO of Globavend stated “This equity line facility provides Globavend with a viable long-term platform to grow its existing operations, expand its e-commerce logistics services into different verticals of the logistics supply chain, enhance its business presence in Australia, New Zealand and Hong Kong, and capitalize on other potential business opportunities. We are always mindful of the best interests of our shareholders and are committed to deliver solid financial performance for the company in 2024 and beyond.”

About Globavend Holdings Limited

Globavend Holdings Limited is an emerging e-commerce logistics provider offering end-to-end logistics solution in Hong Kong, Australia and New Zealand. The Company’s customers are primarily enterprise customers, being e-commerce merchants, or operators of e-commerce platforms, in providing business-to-consumer (B2C) transactions. As an e-commerce logistics provider, the Company provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution, from pre-carriage parcel drop off to parcel consolidation, air-freight forwarding, customs clearance, on-carriage parcel transportation and delivery.

Forward-Looking Statements

This press release contains certain forward-looking statements, including statements with regard to the Company’s proposed transaction and the future potential of the Company. Words such as “will,” future,” “expects,” “believes,” and “intends,” or similar expressions, are intended to identify forward-looking statements. Forward-looking statements are subject to inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed transaction discussed above will be completed on the terms described or achieve the objectives contemplated. Our ability to utilize the financing platform effectively and successfully are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, the failure of customary conditions precedent and the risk factors and other matters set forth in our annual report on Form 20-F. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

For investor and media inquiries, please contact:
Company Info:
Globavend Holdings Limited
Wai Yiu Yau, Chairman and CEO
[e-mail] 61 08 6141 3263

https://www.globenewswire.com/newsroom/ti?nf=OTA2NDkzNiM2MTQwMDkzIzUwMDExOTk3MQ==
https://ml.globenewswire.com/media/MjM0ZWI4MTEtYjI1Zi00ZTg5LTgzZDktOGQ3YjYzMDNmNWFmLTUwMDExOTk3MQ==/tiny/Globavend-Holdings-Limited.png

Source: Globavend Holdings Limited

[FinlayS00]

$IQST waits another acquisition! IQST is in full BULL mode!

[Bansky]

$EBYH Dramatically increased in revenues.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap.

[ProfitScout]

$CETX News: Cemtrex Announces Beta Release of Pioneering AI Gun Detection Feature

Disruptive Artificial Intelligence (AI) Gun Detection Feature to Launch in the Second Calendar Quarter of 2024, Marking a Significant Milestone Achievement for Detecting Armed Persons in Surveillance Footage

Hauppauge, NY, March 06, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today announced that its subsidiary, Vicon, is expected to commence the beta release of its innovative Artificial Intelligence (AI) gun detection feature in the second calendar quarter of 2024, marking a significant milestone in public safety and security technology. This groundbreaking feature is designed to function on edge devices, offering a low-cost, high-efficiency solution for detecting armed persons in surveillance footage and enhancing the capabilities of video management systems to initiate specific responses upon detection.

The introduction of this AI feature, with full commercialization planned for the second half of 2024, is part of Vicon’s commitment to developing cutting-edge solutions that meet the dynamic needs of our customers. This commercialization strategy allows for gathering real-world insights and refining the technology based on feedback from live environments, ensuring the delivery of a superior product experience. Current solutions on the market are generally server-based which are extremely cost prohibitive and difficult to deploy, whereas Vicon’s approach for an edge-based solution, offers a more effective alternative.

Vicon, in collaboration with its technology partners, is developing this feature to provide real-time alerts and facilitate rapid response, thereby playing a crucial role in enhancing security measures and potentially preventing violent incidents before they occur. The value of integrating gun detection technology into video surveillance systems offers significant advancements in the ability of organizations to protect their premises and the people within them, providing peace of mind in increasingly uncertain times.

"Our goal is not only to innovate but to make a meaningful contribution to public safety," said Saagar Govil, CEO of Cemtrex. "The early adoption and feedback through our beta release are vital in shaping a solution that truly meets societal needs. By making advanced gun detection technology accessible and affordable, we aim to equip organizations with the tools they need to enhance their security protocols and respond more effectively to potential threats."

Gun violence remains a pressing issue in the United States, with provisional data for 2022 from the Centers for Disease Control and Prevention highlighting the urgent need for innovative solutions:

Over 48,000 firearm-related deaths, including nearly 20,000 homicides, were recorded in the U.S.
An average, 132 Americans died from a firearm-related injury each day, with hundreds more shot and injured.
Guns remained the leading cause of death for children and teens, climbing 87% in the last decade.
Recent years have seen a stark increase in school shootings, with 2021, 2022 and 2023 all setting records since at least 2008. There were at least 82 incidents in 2023, but 2022 was one of the deadliest years, with 46 fatalities, according to CNN.
Vicon's AI gun detection technology aims to contribute significantly to efforts to reduce gun violence and its devastating impact on communities across the nation. The Company sees the market opportunity for this feature to be vast, ranging from schools, hospitals, government buildings, retail, to religious institutions.

About Cemtrex

Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.

Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit www.vicon-security.com

AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit www.ais-york.com

For more information visit www.cemtrex.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.


https://www.globenewswire.com/newsroom/ti?nf=OTA1OTAyMiM2MTIzNTA1IzIwNDk3MDg=
https://ml.globenewswire.com/media/YmFhNDM0Y2ItNmNiNS00MmQ5LThkNDgtNGYyMDA2ZDBlNWU4LTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235

[e-mail]
www.mzgroup.us

Source: Cemtrex Inc.

[ProfitScout]

$CETX News: Cemtrex Issues Shareholder Letter and Provides Corporate Update

Completed Restructuring in 2023 Now Positions AIS and Vicon Segments for Continued Revenue Growth and Expanded Operating Profitability

Brooklyn, NY, Feb. 28, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today issued a letter to shareholders from Chairman and CEO Saagar Govil.

To the Shareholders of Cemtrex, Inc.,

I wanted to provide you with a detailed update on Cemtrex’s activities over the last several months. If you have been following our progress closely then you will know that we have made many changes to our organization with the hope that we will generate attractive returns for all of you as we go forward. I also wanted to take this opportunity to talk a little bit more in depth about our Company in a way that might provide additional insight into why management has made some of the decisions we have, and how management views the current opportunities in our portfolio.

Over the last five years we have made a number of different investments. Some have proven to be quite fruitful while others, unfortunately, have not led to great results. We cannot change the missteps we have taken, but we have certainly learned from them and learned how to avoid them in the future. While we remain bullish in the emerging opportunities that Cemtrex invested in over the last five years, like Virtual Reality and SmartDesk, it became readily apparent that we could not effectively drive the best outcomes with these long-term investments due to the enormous cash requirements and operating losses that would be required to see these through. Private companies have certain luxuries that public companies do not have when it comes to building startups, particularly in rising interest rate environments. As a result, we made the difficult but ultimately correct decision to exit these businesses.

Looking ahead, we can confidently say that the path we are on today is clearer than ever, with the highest assurance of success that we have had since the Company’s inception. But what does success mean? For us, a company over the long term should be able to generate a higher return with its cash than would be possible by investing it in the S&P 500 index. Everything starts with this fundamental premise. Sadly, today there are many public companies that do not meet this test, including ours in recent years. Over the last ten years, despite making several smart decisions, we made some unforced errors which resulted in relinquishing any positive returns in our common stock that could have been realized. However, despite these setbacks we remain well poised for a positive turnaround on this front. Based on the numerous changes over the last twenty four months and restructuring of our business that we undertook in November of 2022, I am confident that we are on the right track to start consistently driving above average returns. Let’s dive into why that is the case:

With the restructuring completed Cemtrex owns two great businesses: Vicon Industries, Inc. (“Vicon”) which comprises our Security segment, and Advanced Industrial Services, Inc. (“AIS”) which comprises our Industrial segment.

When we make an investment, we primarily look at two measures of capital return efficiency. The first is with respect to our investment. What is the cash-on-cash return of the investment over its life compared to the S&P 500? Additionally, we look at, on an annual basis, what is the Annual Net Income against the starting FY Shareholder’s Equity in the business?

We acquired AIS during our FY 2016 for a total purchase price of $7,500,000. Out of that purchase price, Cemtrex contributed $1,000,000 of equity, which was paid in the form of Cemtrex stock. The balance of the purchase price was financed through debt. Looking at the Net Income of the business, excluding the unusual benefits of COVID-19 relief programs like PPP that took place in 2021, the cumulative return on that investment over the eight years we have owned AIS has been $8,628,084 or 863%. When that cumulative return is averaged over the 8 years ownership it represents a 108% annual return on Cemtrex’s invested capital.

Furthermore, when we look at our second measure for this business, the annual return on equity, we see additional encouraging results. The annual return on beginning shareholder’s equity for AIS, on average, over the last 8 years, again excluding PPP benefits in 2021, has been approximately 35%. This important measure encourages management to continue investing its equity into this business to drive outsized returns. Additional factors that make AIS an attractive business are: 1) approximately 70% of our sales come from repeat customers we do business with; 2) attractive 30%+ gross margins that we see further opportunity to drive higher as we grow the business; 3) the macro-economic factors in the U.S. that are driving growth, including increased infrastructure spending and reshoring of manufacturing.

For FY 2023, AIS produced strong results, with sales reaching $25 million compared to $21.2 million for the prior year, an increase of 18%. Additionally, operating income increased from $.6 million in FY 2022 to $3.1 million in FY 2023, representing a 400% increase in operating earnings for the period.

Regarding our Security segment, let’s focus on our investment in Vicon of which we own 95%. Cemtrex has invested approximately $22.95 million of its own cash into Vicon, as debt and equity, to date over the five years of ownership, including the cost of acquiring the shares of the business as well as additional investments made into the company to grow it. At the time our initial investment was made the market cap of the company was approximately $5.5 million. Today, with the company doing $34.7 million in annual revenue and three sequential quarters of operating profit in FY 2023, we can conservatively estimate the enterprise value of Vicon to be substantially higher than when we made our investment and our return on equity, when annualized over the 5 years of ownership, far exceeds the competing return on the S&P 500.

In FY 2023, Vicon produced significantly better results, with sales growing from $23.8 million in FY 2022 to $34.7 million in FY 2023, an increase of 46%. Gross Profit improved from $8.5 million in FY 2022 to $15.6 million in FY 2023, an increase of 85%. The operating loss at Vicon was reduced from $6.1 million in FY 2022 to $0.6 million in FY 2023, a reduction of 92%, and the Company has had an operating profit three of the last four quarters.

The exciting part is that we believe relative to our current investment, limited additional capital, if any, will be required on Cemtrex’s behalf to drive further growth at Vicon. Based on the continued opportunity for growth, we believe that Vicon has tremendous potential to increase its enterprise value over the next five years that would maintain or exceed the annual return on our capital. This will be accomplished primarily by driving further topline growth, increasing operating profits, and scaling Annual Recurring Revenue (“ARR”) products that we believe can drive multiple expansion.

In our segment reporting we now carve out our Corporate costs, essentially the costs to manage these portfolio companies and the costs of being a public company, as a separate segment so that it is easier for our shareholders to better ascertain the underlying performance of the businesses we own. The Corporate costs today reduce our operating income meaningfully, but as we scale the business these costs will continue to remain at low levels relative to our earnings.

As legendary investor Peter Lynch said, “Often, there is no correlation between the success of a company’s operations and the success of its stock over a few months or even a few years. In the long term, there is a 100% correlation between the success of a company and the success of its stock.” Our goal going forward is to leverage our capital in a way to drive excellent operating results and thus deliver exceptional returns on our investments over time. We remain confident that as we stay on this path the consistent results in the business will begin to be reflected in our stock.

All the above certainly doesn’t summarize all the accomplishments that have taken place within our Company this past year. We have added a number of talented employees, restructured some of our debt to give us greater flexibility for growth, completed an important acquisition at AIS, and launched several exciting products at Vicon that will set it on a path for long term success for years to come. We feel, based on the results above, that FY 2023 represents a key turning point for us, as we have a renewed focus, clarity, and resolve to deliver exceptional results going forward.

Sincerely,

Saagar Govil
Chairman and Chief Executive Officer

About Cemtrex

Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.

Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit www.vicon-security.com

AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit www.ais-york.com

For more information visit http://www.cemtrex.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.



https://www.globenewswire.com/newsroom/ti?nf=OTA1NDkzNyM2MTEyMTUwIzIwNDk3MDg=
https://ml.globenewswire.com/media/YmVkYTQxMGItNDhhMy00MjFhLWJhMTEtZDM5MzJhMmQzNjcwLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235

[e-mail]
www.mzgroup.us

Source: Cemtrex Inc.

[ProfitScout]

$GDHG: Golden Heaven Group Holdings Ltd. Releases 2024 Chairman's Letter to Shareholders
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000724.html

About Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.

[ProfitScout]

$SMME News: SmartMetric says its Gen4 Self Powered Biometric Finger Scan Card Is Perfectly Designed to Meet the Needs of the 518 Million Credit Cards Issued in the United States

February 6, 2024
NEW YORK--(BUSINESS WIRE)-- SmartMetric, Inc. (OTC: SMME) A fingerprint scan credit card is a type of biometric card that uses a built-in fingerprint scanner to verify the identity of the cardholder when they try to make a payment. This technology is designed to enhance the security and convenience of credit card transactions, especially for contactless payments as well as standard contact payments and ATM transactions.

Better protection of your data: Unlike PINs, fingerprint data is encrypted and is only stored in the card, bypassing the need for a central database connected to the internet, protecting a card user’s sensitive data from hackers1. Additionally, the technology safeguards against duplicated 2D and rubber fingerprints because it requires electrical capacitive sensing. In addition, the SmartMetric biometric credit/debit card has an inbuilt hardware based live fingerprint detection created by SmartMetric and only available on the SmartMetric biometric credit/debit card.

Even more convenience: Credit cards save consumers time and allow them to pay quickly. With a fingerprint scan credit card, you don’t need to remember or enter a PIN, which can speed up the checkout process and reduce the risk of forgetting or losing your PIN. At the moment the card issuing brands such as Visa and Mastercard are not proposing to eliminate the use of a PIN with a biometric card. Discussion in Europe by Banking regulators is actively talking about the doing away with the widely accepted “insecure” PIN when users use a fingerprint scan credit/debit card. Credit card networks already have the ability to turn off PIN usage which they do for some low-cost transactions such as buying a coffee. Logic would have it as biometric credit cards proliferate non-PIN usage will expand without restriction to fingerprint biometric scan cards.

Works with existing POS infrastructure: SmartMetric fingerprint scan credit cards are compatible with existing point-of-sale terminals that accept chip or contactless payments, so merchants don’t need to invest in new equipment or software to accept them. However, more recent players who are trying to test reader powered finger scan credit cards that rely on the power from the reader are trapped in having their cards not able to work at most Gas Stations, ATM’s and many restaurants that don’t have portable card readers that are brought to the table.

The stark functional deficits of non-self-powered fingerprint scan credit/debit cards compared to the SmartMetric internally powered ready to use at all times and all situations, fingerprint scan card is best explained in the following.

Non-Self Powered Fingerprint Scan Card

Only works when inserted into a card reader therefore limiting use of the card and not able to be used in all card user situations. These cards rely on the user touching the cards fingerprint sensor while the other end of the card with the contact chip is held in the reader. This allows the card to power the fingerprint scan only through the power from the card reader going into the card. So these cards are limited to readers that only partially insert the card into a reader. Otherwise, they have no power of their own to perform a fingerprint scan. Some of the places these none-powered cards will NOT work in are: ATM’s that swallow the card whole Restaurants that do not have a portable card reader but require the card to be taken from the table for transaction processing Gas station pumps that like ATM’s swallow the card whole Transit ticket dispensers that swallow the card whole Parking station ticket machines that swallow the card whole
Non-Self Powered finger scan credit or debit cards require the user to go to a bank branch to have their fingerprint scanned and then transferred onto the card via a secure fingerprint capture device. This is bothersome to the card user. It raises trust issues about having the bank involved in the capture of the user’s fingerprint. For large scale credit issuers that rely on mass mailing of new and replacement credit cards requiring their customers to have to come into a bank branch just will not work.
SmartMetric Self Powered Finger Scan Card

The SmartMetric self-powered finger scan card because it has its own internal rechargeable power, scans the cared user’s finger prior to the card being inserted into a credit card reader. Therefore, the card is able to be used at all existing and types of credit card readers without the stark limitations of the non-self-powered fingerprint scan cards.
The SmartMetric self-powered finger scan card does not require the card user to go into a bank branch to register their fingerprint on the card. Nor does it alternatively need a separate secure card reading device to be sent out to the card user for in home fingerprint download into the card. The SmartMetric finger scan card user simply touches the cards fingerprint sensor four (4) times an instantly their fingerprint is scanned and securely stored inside the card. No user friction. Instant fingerprint capture and store because the card is self-powered and acts immediately as a fingerprint scanner.
Mass credit card issuers who rely on mail distribution for the credit cards need not to change the way they do business. SmartMetric finger scan cards are easily shipped to homes through the mail and without fuss or user friction are easily set up for future card use by the user’s fingerprint.
The SmartMetric self-powered finger scan card works at ALL card readers such as: ATM’s Restaurants that take the card from the table to process (user touches the sensor which turns on the card for up to 8 minutes giving the table server enough time to have the card processed) Gas pumps Parking ticket vending machines Transit ticket vending machines
“Because of the limitations of the user and card issuer experience we believe that trials and testing of the non-self-powered cards under way in Europe are doomed to failure. Much like inferior electric vehicles are failing in the market while Tesla continues to grow exponentially with its model Y becoming the biggest selling vehicle globally. Failed poorly thought-out products fail because no one wants them while it doesn’t distract from new innovations success trajectory when the new innovators get the product to align with customers expectations,” said SmartMetric’s President and CEO, Chaya Hendrick.

It has taken years of research and development to perfect the internal power system within the SmartMetric finger scan card. Millions of dollars in research and development have been invested to create the only card of its kind in the world that will work at all card readers. A card that is simple to download your fingerprint into the card at home without the fear and inconvenience of going somewhere else to have your fingerprint scanned and stored into the card.

The SmartMetric finger scan card is light years ahead and brings the reality of full biometric security technology to the ubiquitous credit and debit card world.

Credit cards still dominate the way consumer make payments. Non credit card payments such as phones account for less than 5% of payment transactions while the majority of transactions are done using either a credit or debit card.

According to a report published by Forbes Adviser on March 9, 2023 “Over the past year, nearly half the population (47.5%) opened at least one new account, bringing the total number of accounts to over 518 million by the end of 2022.” 1

The mass market version of the SmartMetric Gen4 biometric credit card is now under manufacture following the successful testing of the cards new and advanced internal operating system on the new card hardware platform.

Currently the card is under manufacture which involves the electronic assembly and separately the cards lamination turning it into a credit card is underway in Asia. The cards internal software including its operating system has been tested by the SmartMetric group of engineers in Tel Aviv, Israel.

“While we have experienced unbelievable challenges and delays, we are very excited about being able to very soon show our finished mass production biometric finger scan card to the world,” said Chaya Hendrick.

We are protected by issued patents in the United States with pending patents in Asia and Europe and other parts of the World.

By far our biggest patent protection revolves around issued design patents granted by the USPTO (United States Patent and Trademark Office) that grant protection against any product design such as a smart card or credit chip card that has in any one of multiple variations a fingerprint sensor on it. “None of the other biometric card manufacturers who in our opinion are wasting their time with an inferior none self-powered card, will be able to sell such cards in the United States because of the issued patents,” said Chaya Hendrick.

“Design Patents are easily enforced and the owner or licensee of such patents can have offending products seized at a port of entry or at a place of business in the USA without much effort,” said Chaya Hendrick.

Utility patents can take years of legal fighting however design patents are based on does the product look like what is patented in the design patent and if so then it is infringing.

“We are confident that if a Bank in the USA wants to issue biometric finger scan cards in the USA that have a chip and a fingerprint sensor on them, then they will need to deal with SmartMetric,” said Chaya Hendrick.

To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card.

To view the company website: www.smartmetric.com

1 Credit Card Statistics And Trends 2024 – Forbes Advisor

Safe Harbor Statement: Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Also such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to d iffer materially from current expectations include, among others, if we are unable to access the capital necessary to fund current operations or implement our plans for growth; changes in the competitive environment in our industry and the markets where we operate; our ability to access the capital markets; and other risks discussed in the Company's filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, which filings are available from the SEC. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Investors and security holders are urged to carefully review and consider each of SmartMetric Inc. public filings with the SEC, including but not limited to, if applicable, Annual Reports on Form 10-K, proxy statements, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240206872799r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206872799/en/

SmartMetric, Inc.
Chaya Hendrick
Tel: [phone]
Mobile: [phone] (Pacific Time)
[e-mail]
http://www.smartmetric.com

Source: SmartMetric, Inc

[ProfitScout]

$SRM Feature Article: Strong Consumer Market for NASDAQ Coming Off Original $5 IPO with New Toy & Souvenir Products for Top Clients: $SRM
Click here:
https://www.einpresswire.com/article/686503802/strong-consumer-market-for-nasdaq-coming-off-original-5-ipo-with-new-toy-souvenir-products-for-top-clients-srm